Skip to content
PubMed This is a summary of 79 peer-reviewed journal articles Updated
Rheumatology

Understanding Your Diagnosis: Microscopic Polyangiitis (MPA)

At a Glance

Microscopic Polyangiitis (MPA) is a rare autoimmune condition that causes inflammation in the body's small blood vessels, most commonly affecting the kidneys and lungs. With modern induction and maintenance therapies, long-term remission is now the standard goal for most patients.

Hearing the name Microscopic Polyangiitis (MPA) for the first time can be overwhelming, especially since it is a rare condition that most people—and even many local doctors—have never encountered [1]. It is completely normal to feel anxious or confused. However, while the name is complex, the medical community’s understanding of how to manage it has grown tremendously in recent years.

MPA is a type of vasculitis—a general term for inflammation of the blood vessels [2]. In MPA, the immune system mistakenly attacks the smallest blood vessels in the body, such as capillaries, arterioles, and venules [2][3]. Because these tiny vessels are located everywhere, the disease can affect multiple organs, though it most frequently involves the kidneys and lungs [2][4]. It is often grouped under the umbrella of ANCA-associated vasculitis (AAV) because most patients test positive for ANCA (anti-neutrophil cytoplasmic antibodies), which are proteins in the blood that play a role in the vessel damage [2][5].

Three Stabilizing Facts for the Newly Diagnosed

If you are feeling unmoored by this diagnosis, keep these three evidence-based facts in mind:

  1. Remission is the Standard Goal: Modern medicine is highly effective at stopping the “fire” of active inflammation. With current induction therapy (initial treatment to stop the disease), the vast majority of patients achieve remission, a state where the disease is no longer active [6][7].
  2. Survival Rates Have Dramatically Improved: Historically, MPA was difficult to treat, but advances in the last few decades have shifted the focus from short-term survival to long-term health management [8]. Most patients now lead full lives by managing the condition as a chronic illness [9].
  3. Treatment Is Becoming “Steroid-Sparing”: In the past, high doses of steroids were the only option. Today, new medications like avacopan and rituximab allow doctors to control the disease while significantly reducing the amount of prednisone needed, which helps minimize side effects [6][10].

Understanding the Disease Course

MPA typically moves through two main phases:

  • Induction Phase: This is the initial stage where doctors use strong medications to quickly stop the immune system from attacking your blood vessels [6]. This usually lasts 3 to 6 months. While full remission takes months, many patients notice improvements in severe fatigue and joint pain within the first few weeks of starting high-dose steroids.
  • Maintenance Phase: Once the disease is quiet (in remission), you will switch to milder medications designed to keep the immune system stable and prevent the disease from returning, which is called a relapse [11][12].

Why It Is Often Missed Initially

Because MPA is so rare—occurring in roughly 1 to 10 people per million each year—it is often not the first thing a doctor suspects [1]. Symptoms like fatigue, weight loss, or joint pain can look like many other common illnesses [1]. If you felt that your diagnosis took a long time or required many tests, it is not your fault; the rarity of the condition often requires a specialist, such as a rheumatologist or nephrologist, to correctly identify it [12][13].

Common Signs and Monitoring

While MPA affects everyone differently, doctors will closely monitor certain areas of your health:

  • Kidneys: About 80% of patients experience kidney inflammation, often detected by blood or protein in the urine [13].
  • Lungs: Some patients develop a cough or shortness of breath. In rare, serious cases, this can involve bleeding in the lungs, which requires immediate attention [14][15].
  • Nerves and Skin: You may notice tingling or numbness in your hands and feet, or small purple spots on your skin called purpura [1].

Identifying these symptoms early and beginning treatment is the most important step in protecting your long-term health [8].

To learn more about your disease and how to navigate it, explore the rest of this guide:

Patient Tip: Connecting with patient advocacy groups, such as the Vasculitis Foundation, can offer invaluable peer support and mental health resources to help you through your journey.

Common questions in this guide

What does an ANCA positive test mean for Microscopic Polyangiitis?
An ANCA positive result means you have anti-neutrophil cytoplasmic antibodies in your blood. These proteins cause your immune system to mistakenly attack your small blood vessels, leading to the inflammation seen in MPA.
Is it possible to go into remission with MPA?
Yes, achieving remission is the standard goal of modern MPA treatment. With prompt induction therapy to stop active inflammation, the vast majority of patients reach a state where the disease is no longer active.
Which organs are most affected by Microscopic Polyangiitis?
MPA most frequently affects the kidneys and lungs. Doctors will closely monitor your kidney function through urine tests and watch for lung symptoms like a new cough or shortness of breath.
What are the treatment phases for MPA?
Treatment typically starts with an induction phase using strong medications to quickly stop blood vessel inflammation. Once in remission, patients move to a maintenance phase with milder drugs to prevent the disease from returning.
Can MPA be treated without high doses of steroids?
Yes, modern treatment is increasingly 'steroid-sparing'. Newer medications like avacopan and rituximab can effectively control the disease while significantly reducing the need for high doses of prednisone.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my current ANCA status, and are the antibodies directed against MPO or PR3?
  2. 2.How many other patients with MPA or ANCA-associated vasculitis have you treated in the last year?
  3. 3.Which organ systems are currently affected by my vasculitis, and how will we monitor them specifically?
  4. 4.Can we use a 'steroid-sparing' treatment plan to minimize the side effects of prednisone?
  5. 5.Is there a vasculitis specialist or center of excellence you can coordinate my care with?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Incidence and prevalence of granulomatosis with polyangiitis and microscopic polyangiitis in health management organization in Argentina: a 15-year study.

    Pierini FS, Scolnik M, Scaglioni V, et al.

    Clinical rheumatology 2019; (38(7)):1935-1940 doi:10.1007/s10067-019-04463-y.

    PMID: 30746579
  2. 2

    Microscopic Polyangiitis: New Insights into Pathogenesis, Clinical Features and Therapy.

    Karras A

    Seminars in respiratory and critical care medicine 2018; (39(4)):459-464 doi:10.1055/s-0038-1673387.

    PMID: 30404112
  3. 3

    Treating elderly patients with ANCA-associated vasculitis.

    Jefferson JA

    Clinical journal of the American Society of Nephrology : CJASN 2015; (10(7)):1110-3 doi:10.2215/CJN.05350515.

    PMID: 26100458
  4. 4

    Clinical features and prognosis of microscopic polyangiitis with usual interstitial pneumonia compared with idiopathic pulmonary fibrosis.

    Zhao W, Dai H, Liu Y, et al.

    The clinical respiratory journal 2019; (13(7)):460-466 doi:10.1111/crj.13032.

    PMID: 31013398
  5. 5

    Pathogenesis and pathology of anti-neutrophil cytoplasmic antibody(ANCA)-associated vasculitis.

    Tsukui D, Kimura Y, Kono H

    Journal of translational autoimmunity 2021; (4()):100094 doi:10.1016/j.jtauto.2021.100094.

    PMID: 33912820
  6. 6

    New therapeutic strategies in lung vasculitis.

    Nasser M, Cottin V

    Current opinion in pulmonary medicine 2020; (26(5)):496-506 doi:10.1097/MCP.0000000000000693.

    PMID: 32740376
  7. 7

    Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial.

    Furuta S, Nakagomi D, Kobayashi Y, et al.

    JAMA 2021; (325(21)):2178-2187 doi:10.1001/jama.2021.6615.

    PMID: 34061144
  8. 8

    Diagnosis and management of ANCA-associated vasculitis.

    Kronbichler A, Bajema IM, Bruchfeld A, et al.

    Lancet (London, England) 2024; (403(10427)):683-698 doi:10.1016/S0140-6736(23)01736-1.

    PMID: 38368016
  9. 9

    Recent pathogenetic insights and therapeutic advances in ANCA-associated vasculitis.

    Sagy I, Jayne DRW

    Annals of the rheumatic diseases 2026; (85(4)):588-602 doi:10.1016/j.ard.2025.11.024.

    PMID: 41469274
  10. 10

    Avacopan for the Treatment of ANCA-Associated Vasculitis.

    Jayne DRW, Merkel PA, Schall TJ, et al.

    The New England journal of medicine 2021; (384(7)):599-609 doi:10.1056/NEJMoa2023386.

    PMID: 33596356
  11. 11

    Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.

    Terrier B, Pagnoux C, Perrodeau É, et al.

    Annals of the rheumatic diseases 2018; (77(8)):1150-1156 doi:10.1136/annrheumdis-2017-212768.

    PMID: 29724729
  12. 12

    Recommendations for the diagnosis and treatment of anti-neutrophil cytoplasmic autoantibody associated vasculitis.

    Morales E, Rúa-Figueroa I, Callejas Rubio JL, et al.

    Nefrologia 2025; (45(1)):15-58 doi:10.1016/j.nefroe.2025.01.001.

    PMID: 39855968
  13. 13

    Kidney biopsy in patients with antineutrophil cytoplasmic antibody-associated vasculitis with mild renal abnormality.

    Akao S, Yamagiwa G, Hazue R, et al.

    CEN case reports 2023; (12(1)):50-55 doi:10.1007/s13730-022-00719-w.

    PMID: 35817952
  14. 14

    Myeloperoxidase anti-neutrophil cytoplasmic antibody-associated vasculitis with silicosis, alveolar hemorrhage, and rapidly progressive glomerulonephritis: a case report.

    Mizuhashi K

    AME case reports 2025; (9()):8 doi:10.21037/acr-24-112.

    PMID: 39866275
  15. 15

    Hemoptysis as the initial presentation of ANCA-associated vasculitis in a patient with ulcerative colitis: a case report and literature review.

    Fan MH, Wu J, Min CC, et al.

    Clinical rheumatology 2026; (45(3)):2089-2095 doi:10.1007/s10067-025-07878-y.

    PMID: 41400921

This page is for informational purposes only and does not replace professional medical advice. Always consult your rheumatologist or nephrologist about your specific Microscopic Polyangiitis diagnosis and treatment plan.

Get notified when new evidence is published on Microscopic polyangiitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.